Search
Now showing items 51-60 of 75
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.
(
Nature Research
, 2022 , Article)
SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 ...
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
(
Nature Research
, 2022 , Article)
There is significant genetic distance between SARS-CoV-2 Omicron (B.1.1.529) variant BA.1 and BA.2 sub-lineages. This study investigates immune protection of infection with one sub-lineage against reinfection with the other ...
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
(
Massachusetts Medical Society
, 2022 , Article)
Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to expedited ...
Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections.
(
Springer
, 2022 , Article)
SARS-CoV-2 breakthrough infections in vaccinated individuals and in those who had a prior infection have been observed globally, but the transmission potential of these infections is unknown. The RT-qPCR cycle threshold ...
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.
(
Massachusetts Medical Society
, 2022 , Article)
The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) ...
Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
(
MDPI
, 2022 , Report)
The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was ...
Effectiveness of mRNA booster doses against the omicron variant
(
Elsevier
, 2022 , Other)
Since its emergence in November, 2021, the omicron (B.1.1.529) variant of SARS-CoV-2 has rapidly spread and quickly overtaken the delta (B.1.617.2) variant as the most common cause of infection.1 Due to numerous spike ...
Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar.
(
Public Library of Science
, 2017 , Article)
The Epstein-Barr virus (EBV) is the causative agent of infectious mononucleosis. EBV is highly prevalent lymphotropic herpesvirus and has been linked to several malignancies. Transmission is generally by oral secretions, ...
Herpes Simplex Virus Type 2 Seroprevalence Among Different National Populations of Middle East and North African Men
(
Lippincott, Williams & Wilkins
, 2018 , Article)
BACKGROUND:
There are limited data on herpes simplex virus type 2 (HSV-2) seroprevalence in the Middle East and North Africa (MENA). We examined country- and age-specific HSV-2 seroprevalence among select MENA populations ...
Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections
(
Frontiers Media
, 2022 , Article)
In 2021, Qatar experienced considerable incidence of SARS-CoV-2 infection that was dominated sequentially by the Alpha, Beta, and Delta variants. Using the cycle threshold (Ct) value of an RT-qPCR-positive test to proxy ...